revenues for the year 2015 and 2016 were 65.7% and 64.3% respectively. The major operating cost comprised 1) doctor’s fee 2) Salaries, wages and other employee benefits 3) inventories used 4) depreciation
) 2019 (01/01/19 -31/12/19) Accounting Type Consolidate Consolidate Consolidate Consolidate Consolidate Operating Cash Flow -106.82 95.87 145.00 321.28 -42.77 Investing Cash Flow -48.58 -53.71 -71.68
) 2021 (01/01/21 -31/12/21) 2020 (01/01/20 -31/12/20) 2019 (01/01/19 -31/12/19) Accounting Type Consolidate Consolidate Consolidate Consolidate Consolidate Operating Cash Flow 43.11 25.63 78.09
Consolidate Consolidate Consolidate Operating Cash Flow 140.59 -62.50 -48.75 130.23 -3.66 Investing Cash Flow 300.54 -57.62 -138.74 -274.05 -126.85 Financing Cash Flow -128.56 -13.76 42.14 281.56 38.56 Net Cash
Consolidate Consolidate Consolidate Operating Cash Flow -116.51 -73.65 -161.84 205.80 -104.16 Investing Cash Flow -20.38 -8.60 10.74 -15.69 -101.30 Financing Cash Flow 184.72 -165.41 -130.21 110.71 221.05 Net
(01/01/21 -31/12/21) 2020 (01/01/20 -31/12/20) 2019 (01/01/19 -31/12/19) Accounting Type Consolidate Consolidate Consolidate Consolidate Consolidate Operating Cash Flow 61.15 51.48 139.16 199.13
Baht 23 million from the balance at the ended of 31 December 2018. This were mainly because there was an increase in cash and cash equivalent the Company reserves to pay the dividend, and trade and other
Company and subsidiaries as follows: S&P Syndicate PCL and subsidiaries operating performance for 2nd quarter Ending 30 Jun 2019 Revenue from Sales and Services In the second quarter of year 2019, the
the balance at the ended of 31 December 2018. This were mainly because there was a decrease in trade and other receivables from sales and inventory as the Company sold a large amount of trading products
at the ended of 31 December 2018. This were mainly because there was a decrease in trade and other receivables from sales and inventory as the Company sold a large amount of trading products in the